# Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

> **NCT00731731** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 125 (actual)

## Conditions studied

- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma

## Interventions

- **RADIATION:** 3-Dimensional Conformal Radiation Therapy
- **PROCEDURE:** Cognitive Assessment
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Temozolomide
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT00731731
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-10
- **Primary completion:** 2014-02-02
- **Final completion:** 2019-11-01
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2022-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00731731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00731731, "Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00731731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*